Shenzhen HANK Bioengineering

Shenzhen HANK Bioengineering is a clinical-stage biotechnology company based in China that focuses on the development of Natural Killer (NK) cell-based immunotherapies. The company's core technology is the HANK (Highly Activated NK) platform, which enables the large-scale expansion and activation of NK cells for therapeutic use. Their pipeline includes autologous and allogeneic NK cell products for treating various solid tumors, hematological cancers, and viral infections such as COVID-19 and Hepatitis B. Additionally, the company is advancing CAR-NK cell therapies to improve targeting and efficacy against specific cancer antigens. HANK Bioengineering operates GMP-compliant manufacturing facilities to support its clinical programs and future commercialization efforts.